Lipigon Pharmaceuticals AB Company Description

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden.

Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia.

The company has a license agreement with Leaderna for the development of Lipisense. The company was incorporated in 2010 and is based in Umeå, Sweden.

Lipigon Pharmaceuticals AB (publ)

Country	Sweden
Founded	2010
Industry	Pharmaceutical Preparations
Employees	7
CEO	Johan Liwing

Contact Details

Address: Tvistevägen 48 C Umeå, 90736 Sweden
Phone	46 7 06 70 36 75
Website	lipigon.se

Stock Details

Ticker Symbol	9RP
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	SEK
SIC Code	2834

Key Executives

Name	Position
Johan Liwing	Chief Executive Officer
Hugo Petit	Chief Financial Officer